News

Eli Lilly and Company has reported promising new data from Phase III Next trial which showed that arzoxifene, an investigational selective estrogen receptor modulator, was superior to raloxifene

For the year ended December 31, 2008, the company reported a net loss of $28.15 million, or $1.42 per share, compared to a net loss of $28.1 million,

The company reported net revenues of C$2 million for the first quarter of 2009, compared to C$599,000 for the same period of 2008. Luc Tanguay, senior executive vice

Zemiva is a molecular imaging radiopharmaceutical the company is developing to detect cardiac ischemia, the lack of sufficient blood flow to the heart. In this trial, the combination

Attract-1 has been enrolling patients in a variety of other countries since it began in April 2008. Extension of the trial to Japan follows the successful completion of

According to the company, Soar Dynamic Screening demonstrates a new approach to healthcare by providing men a detailed analysis of their prostate health based on several factors beyond

For the year ended December 31, 2008, the company reported a net loss of $12.69 million, or $0.19 per share, compared to a net loss of $8.58 million,

For the year ended December 31, 2008, the company reported a net loss of $22.61 million, or $0.42 per share, compared to a net loss of $24.2 million,

Endo Pharmaceuticals, a developer and marketer of branded and generic prescription pharmaceuticals, has reported the successful completion of the tender offer by its wholly owned subsidiary, BTB Purchaser,